Posted from: Tuesday, September 05, 2017 - 03:54 PM - Present

Nikita Approved for Cholesterol

August 4, 2017 – The U.S. FDA has approved Nikita™ (pitavastatin sodium) tablets, manufactured by Lupin. Nikita is indicated to regulate cholesterol, lipoprotein, and triglyceride levels for patients who have primary hyperlipidemia or mixed dyslipidemia, and should be used in combination with diet changes and exercise. With a recommended dosing of once per day, Nikita tablets will be available in 1mg, 2mg, and 4mg dosage strengths.

Approval for Nikita was obtained through the FDA’s 505(b)(2) pathway, which allowed Lupin to use Livalo® (pitavastatin calcium), manufactured by Kowa Company, as a reference product. Nikita is an alternate salt product, meaning that it is not considered a generic of Livalo, and is not automatically interchangeable. No pricing or launch plans have been announced.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Monday, November 20, 2017 - 03:06 PM.